Enzyvant Expands Leadership Team with Appointments of Andrew Dawson and Alex Tracy
BASEL, Switzerland, July 30, 2018 /PRNewswire/ -- Enzyvant, a biopharmaceutical company focused on developing innovative therapies for patients with rare diseases, today announced the appointments of Andrew Dawson as Senior Vice President of Human Resources and Alex Tracy, PhD as Vice President of Pharmaceutical Development and Manufacturing.
"We are privileged to have Andrew and Alex join the Enzyvant leadership team," said Alvin Shih, MD, Chief Executive Officer of Enzyvant. "Given the recent initiation of our rolling BLA submission for RVT-802, Enzyvant is entering an important period of growth. Both Andrew and Alex will contribute meaningfully to our organization's ability to develop and deliver innovative therapies for rare disease patients."
Mr. Dawson is a veteran human resources executive with 17 years of global experience across the biotech and pharmaceutical industry. He joins Enzyvant after having served in roles of increasing scope and responsibility at Shire, where he was the Vice President of Human Resources for the Global Product Strategy and Corporate Functions. He has also served in senior roles at Roche, Novartis, Eli Lilly, and TripAdvisor. Mr. Dawson received his MSc in Human Resources Management and Development from the University of Salford in Manchester, England.
Dr. Tracy has approximately 20 years of experience in pharmaceutical product development and manufacturing for both biologic and small molecule products across a broad range of dosage forms. Dr. Tracy began his career at Bayer Biologics, and has held senior positions in product development at KBI Biopharma, Novartis Vaccines, Hospira/Pfizer, and Roivant Sciences. Dr. Tracy holds a PhD in Biochemistry and Molecular Biology from the University of Georgia, an MS in Chemistry from George Mason University and a BS in Chemistry from the College of William and Mary.
Enzyvant is a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases. Enzyvant has initiated a rolling BLA submission with the FDA for RVT-802, an investigational tissue-based therapy for the treatment of primary immunodeficiency associated with complete DiGeorge Anomaly.
Enzyvant is simultaneously preparing to initiate a clinical trial of RVT-801, an investigational enzyme replacement therapy for the treatment of Farber disease. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
For more information, please visit www.enzyvant.com.
Contact: Tamara Joseph, email@example.com